Skip to main content
RYET
NASDAQ Technology

Ruanyun Signs Exclusive Malaysia Healthcare AI License With BioNexus Gene Lab

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Education Stocks · Consumer
Sentiment info
Positive
Importance info
7
Price
$0.698
Mkt Cap
$26.1M
52W Low
$0.64
52W High
$2.03
52W Position info
9.0% above low
Off High info
66% below high
Rel. Volume
Market data snapshot near publication time

RYET is trading near its 52-week low of $0.64 (9.0% above the low).

Summary

Ruanyun signed a definitive exclusive license of its Cogni AI platform for Malaysian healthcare to BioNexus Gene Lab, paid in 410,000 BGLC shares nominally worth US$3.5M but quoted at only about US$520,700, plus a 10% royalty and a reciprocal share swap. The deal has not closed and hinges on acceptance testing, approvals and a PRC license Ruanyun has not yet obtained.


Key Events · M&A and Partnerships · RYET

  • Exclusive Malaysia Healthcare License Signed

    Ten-year initial term, renewable for up to two further five-year periods (up to 20 years), exclusive in Malaysian healthcare; BGLC may add other industries in Malaysia by notice, with exclusivity only if a customer contract is signed within 12 months.

  • US$3.5M Paid in Stock, Worth Far Less

    Consideration is 410,000 BGLC shares, not cash. At the October 2, 2026 closes of $1.27 (BGLC) and $0.8599 (RYET), those shares were quoted at US$520,700 — the filing states the US$3.5M is a contractual amount, not market value or revenue.

  • Reciprocal Swap Dilutes RYET

    RYET will issue 500,000 new ordinary shares to BGLC for 150,000 BGLC shares; the RYET shares were quoted at US$429,950 at the October 2 reference price. Royalty is 10% of qualifying technology receipts with no minimum or guaranteed volume.

  • Closing Contingent, PRC License Missing

    Closing requires BGLC's written acceptance after testing, mutual due diligence, corporate and regulatory approvals, and a PRC approval, registration or license RYET has not yet obtained; either party may terminate if closing has not occurred by March 31, 2027.


Analysis · RYET · Technology

Ruanyun is licensing its Cogni AI document-intelligence platform exclusively for Malaysian healthcare to Nasdaq-listed BioNexus Gene Lab for an initial ten years, renewable up to 20. The headline US$3.5M license consideration is paid entirely in BGLC stock, not cash — and at the October 2, 2026 closing prices those 410,000 shares were worth only about US$520,700, so the contractual figure overstates what Ruanyun actually receives. The real economics are a 10% royalty on collections with no minimum, plus a reciprocal swap in which Ruanyun issues 500,000 new shares (worth roughly US$430,000 at the same reference price) to take 150,000 BGLC shares. Nothing has closed: BGLC must accept the technology after testing, both sides must clear due diligence and approvals, and Ruanyun still needs a PRC approval or license it has not obtained. The March 31, 2027 long-stop date means the deal can simply lapse. This is a genuine new-market, new-industry step for the Formind strategy, but it is contingent, non-cash and small in dollar terms relative to the announcement language.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RYET was trading at $0.70 on NASDAQ in the Technology sector, with a market capitalization of approximately $26.1M. The 52-week trading range was $0.64 to $2.03. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RYET - Latest Insights

RYET
Oct 09, 2026, 5:20 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.9199
Real-time Price: $0.4705 info
Change: Low Volume info
Market Cap: $17.54M info
RYET
Oct 02, 2026, 9:09 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.8307
Real-time Price: $0.4705 info
Change: Low Volume info
Market Cap: $17.54M info
RYET
Sep 02, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.7958
Real-time Price: $0.4705 info
Change: Low Volume info
Market Cap: $17.54M info
RYET
Aug 27, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.9751
Real-time Price: $0.4705 info
Change: Low Volume info
Market Cap: $17.54M info
RYET
Aug 20, 2026, 9:25 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.02
Real-time Price: $0.4705 info
Change: Low Volume info
Market Cap: $17.54M info